Novartis’ Kisqali Cuts Death Risk 19% in Breast Cancer Study
Six-year data showed a 19% lower death risk and better invasive disease-free survival for patients taking the drug with hormone therapy, researchers said.
- On Friday, Novartis reported that its breast cancer drug Kisqali extended survival for women with high-risk, early-stage disease by 19% after six years, according to trial data presented at the European Society for Medical Oncology congress in Madrid.
- The NATALEE study shows Kisqali works by slowing cancer cells rather than killing them immediately, bolstering the case for its use to prevent recurrence in patients already approved for stage 2 or 3 breast cancer.
- At six years, 91.9% of women treated with Kisqali and hormone therapy were alive compared with 89.7% of those receiving hormone therapy alone. "Turns out we're seeing a difference even sooner," said UCLA's Dennis Slamon, the trial's lead investigator.
- Analysts project annual sales of about $7 billion for Kisqali this year according to Visible Alpha estimates. Survival benefits persisted even though patients had been off the drug for more than three years on average, Slamon said.
- Showing the drug helps patients live longer is clinically significant, as this breast cancer type can return years after initial treatment. The trial included a broad patient population, including women whose cancer had not spread to lymph nodes.
13 Articles
13 Articles
Novartis' breast cancer drug cuts risk of death by 19% after six years ...
Novartis’ Kisqali Cuts Death Risk 19% in Breast Cancer Study
In combination with endocrine therapy (Et), at 6 years, the risk of death was reduced by approximately 20% (19.1%) compared to endocrine therapy alone in the wider population of patients with breast cancer with positive hormonal receptors and without expression of Her2 protein (Hr+/Her2−) at an early stage, [...]
Rec News | Lontani dal mainstream
In combination with endocrine therapy (Et), at the age of 6, it reduced the risk of death by approximately 20% (19.1%) compared to endocrine therapy alone in the wider population of patients with breast cancer with positive hormonal receptors and without expression of Her2 protein (Hr+/Her2−) early on, [...] The article Initial breast cancer, ribocyclib reduces the risk of death by 20% at 6 years comes from Rec News.
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
